This dataset contains summary data visualizations and clinical data from a broad sampling of 494 prostate adenocarcinomas from 494 patients. The data was gathered as part of the PanCancer Atlas initiative, which aims to answer big, overarching questions about cancer by examining the full set of tumors characterized in the robust TCGA dataset. The clinical data includes mutation count, information...

This dataset contains summary data visualizations and clinical data from the targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay. The clinical data includes mutation count, information about mutated genes, tumor mutational burden calculations, tissue site from which the sample was derived, tumor purity among other relevant data points. The data set also includes copy-number segment...

This dataset contains summary data visualizations and clinical data from a broad sampling of 504 prostate tumor samples from 451 patients. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, patient age, Clinical Gleason, Clinical...

This dataset contains summary data visualizations and clinical data from a broad sampling of prostate adenocarcinomas. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, patient demographics, tumor sample details, Impact TMB Score,...

This dataset contains summary data visualizations and clinical data from a sampling of 18 prostate tumor samples from 10 patients. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes deidentified patient and sample IDs, mutation count, and the fraction of genome that was altered. The data set also includes copy-number segment data downloadable as .seg...

This dataset contains summary data visualizations and clinical data from 67 samples from 67 patients as part an NCI-60 cell line project to compile NCI-60 cell line high-throughput and high-content data into CellMiner, a genomic and pharmacologic database created by the National Cancer Center Institute. The clinical data includes deidentified patient and sample IDs, mutation counts, detailed cancer...

TCGA Bladder Urothelial Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 413 carcinomas from 412 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...

TCGA Prostate Adenocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 501 carcinomas from 500 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...

This dataset contains summary data visualizations and clinical data from a broad sampling of 334 prostate adenocarcinomas from 334 patients. The clinical data includes mutation count, information about mutated genes, patient demographics, tumor sample details, Subtype, Absolute Extract Ploidy, Absolute Extract Purity, Absolute Genome Doublings, AKT1 Mutation , AR mRNA, AR Protein, AR Score, AR V7...

Author summary from Gene Expression Omnibus: "Transcriptome prolifing analysis was performed in 22Pc-EP cells to identify differentially regulated genes by enzalutamide and NRG1. 22Pc-EP cells were treated with androgen receptor inhibition (enzalutamide) or a HER3 ligand NRG1 for 48hrs." The data is from a study on tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer.